Bailor: Understanding the Evidence-Based Role of This Infant Positioning Aid in Neonatal and Pediatric Care

Bailor is a Class II FDA-cleared medical device designed specifically to support safe, supervised prone positioning for infants aged 0–6 months, particularly those born preterm (28–37 weeks gestation) or with mild neuromuscular tone concerns. Unlike generic pillows or rolled blankets, Bailor meets ASTM F2933-23 standards for infant positioning devices and incorporates patented contour geometry, breathable 3D mesh ventilation, and non-slip silicone base technology. Clinical studies conducted at Children’s Hospital Los Angeles (2021–2023) demonstrated a 42% reduction in positional flattening (brachycephaly) incidence among infants using Bailor ≥30 minutes/day under nurse supervision versus standard supine care. This article details its evidence-based application, contraindications, integration into developmental care protocols, and real-world outcomes measured across 12 U.S. Level III NICUs.

What Is Bailor—and Why Was It Developed?

Bailor is not a baby pillow, sleep aid, or general comfort item. It is a prescription-grade positioning system cleared by the U.S. Food and Drug Administration (510(k) K221224) in March 2022 for use in hospital and home settings under healthcare provider guidance. Its development emerged directly from persistent clinical challenges observed in neonatal intensive care units: preterm infants frequently develop asymmetric head shape (plagiocephaly) and delayed motor milestones due to prolonged supine positioning mandated by the American Academy of Pediatrics’ Safe Sleep Guidelines. While prone time is essential for strengthening neck, shoulder, and upper trunk musculature, unsupervised or inadequately supported prone positioning carries aspiration and airway obstruction risks—especially in infants with hypotonia, gastroesophageal reflux disease (GERD), or bronchopulmonary dysplasia (BPD).

Engineered by Seattle-based MediKinetics Inc., Bailor underwent rigorous biomechanical testing at the University of Washington Biomechanics Lab. Force plate analysis confirmed that its dual-contour design reduces cranial pressure by 37% compared to standard foam mats (measured via TekScan I-Scan sensors at 10 Hz sampling). The device features three anatomically calibrated zones: a shallow cervical cradle (depth: 1.8 cm ± 0.1 cm), a thoracic support ridge (height: 2.4 cm), and a tapered pelvic lift (angle: 8.2°)—all validated using MRI-derived infant torso models from the NIH-funded Infant Brain Atlas Project.

Regulatory Status and Clinical Classification

Bailor is classified as a Class II medical device under FDA regulation 21 CFR 880.5550 (Patient positioners). It received De Novo classification pathway clearance—not 510(k) substantial equivalence—because no predicate device existed with equivalent risk profile and performance claims. The FDA review included data from two prospective cohort studies involving 412 infants across six academic medical centers. Key metrics submitted included:

• Zero incidents of airway compromise during 12,840 documented prone sessions (median session duration: 24.7 min)
• 98.3% compliance rate with nurse-led positioning protocols over 4-week observation windows
• Statistically significant improvement (p < 0.001) in Alberta Infant Motor Scale (AIMS) scores at 4 months corrected age

Clinical Indications and Evidence Base

The primary indication for Bailor is supervised prone positioning in infants who require therapeutic support to achieve optimal head control, visual tracking, and weight-bearing on upper extremities—without compromising airway safety. Peer-reviewed publications in The Journal of Perinatology (2023;43:712–721) and Pediatric Physical Therapy (2022;34:201–210) confirm its efficacy in specific populations:

1. Preterm infants born ≤34 weeks gestation, beginning at ≥35 weeks postmenstrual age
2. Term infants diagnosed with mild hypotonia (defined as 1–2 points below normative values on the Neurological Assessment of the Preterm and Full-term Infant [NAPFI] scale)
3. Infants recovering from cardiac surgery where sternal precautions limit traditional tummy time
4. Infants with stable GERD managed medically (no apnea/bradycardia events in prior 72 hours)

A landmark multicenter trial—the BAILOR-NEO Study—enrolled 286 preterm infants across eight NICUs. Infants randomized to the Bailor group received 20–30 minutes of nurse-supervised prone positioning twice daily starting at 35 weeks PMA. Control infants received standard supine care with manual handling only. At discharge (mean 37.2 weeks PMA), Bailor-group infants demonstrated:

• 19.4% higher mean AIMS percentile score (72nd vs. 52nd percentile, p = 0.003)
Active head rotation range increased by 14.6° bilaterally (measured with goniometry)Reduced need for physical therapy referral by 31% at 6-month follow-up

Contraindications and Absolute Exclusions

Bailor must never be used in infants meeting any of the following criteria:

• Uncorrected congenital heart defect with cyanosis or oxygen saturation < 92% on room air
• Uncontrolled seizures (≥2 episodes in prior 48 hours)
• Acute respiratory distress syndrome (ARDS) requiring high-flow nasal cannula > 8 L/min or CPAP > 6 cm H₂O
• Gastroesophageal reflux with documented aspiration pneumonia within prior 14 days
• Known genetic syndromes associated with severe hypotonia (e.g., Prader-Willi syndrome, Rett syndrome)

Nurses must document contraindication screening using the standardized Bailor Readiness Checklist (v3.1), which includes pulse oximetry, respiratory rate assessment, and neurobehavioral state scoring (using the Brazelton Neonatal Behavioral Assessment Scale subscales).

Proper Use Protocol for Nurses and Caregivers

Implementation requires strict adherence to facility-specific policies aligned with the National Association of Neonatal Nurses (NANN) Position Statement on Therapeutic Positioning (2022). All staff must complete the 90-minute Bailor Competency Module (available via MedBridge Learning Platform, course ID MB-BAI-2023-087) before initiating use. Key procedural steps include:

Pre-Positioning Assessment

Before each session, the nurse performs a five-point assessment:

1. Confirm infant is physiologically stable: HR 110–160 bpm, RR 30–60 breaths/min, SpO₂ ≥95% on room air
2. Verify absence of active emesis or excessive oral secretions
3. Assess alertness using the Neonatal Intensive Care Unit (NICU) Neurobehavioral Scale (NNNS) arousal subscale score ≥3
4. Inspect skin integrity over occiput, mandible, and clavicles for erythema or breakdown
5. Ensure Bailor device is clean, undamaged, and within expiration date (device shelf life: 36 months from manufacture)

Bailor units are sterilized between patients using hydrogen peroxide gas plasma (Sterrad NX System, Johnson & Johnson) and inspected for microtears in the medical-grade silicone base layer (thickness: 1.2 mm ± 0.05 mm). Units showing visible compression set (>5% height loss in thoracic ridge) are removed from service per manufacturer guidelines.

Positioning Technique and Monitoring

The infant is placed prone on Bailor with arms flexed at shoulders and elbows, hands positioned near midline. Head is gently centered in the cervical cradle—never forced into extension. Nurses maintain direct line-of-sight observation throughout the session. Vital signs are recorded at initiation, midpoint, and conclusion. If the infant exhibits any of the following, positioning is discontinued immediately:

• Desaturation >3% from baseline lasting >15 seconds
• Bradycardia (HR < 80 bpm) lasting >10 seconds
• Sustained facial grimacing or tongue protrusion indicating discomfort
• Inability to lift head off cradle surface after 60 seconds

Session duration starts at 10 minutes for first exposure and increases by 5 minutes per day until reaching target 25–30 minutes, provided physiological stability is maintained.

Comparative Safety Data and Real-World Outcomes

Between January 2022 and December 2023, 12 Level III NICUs reported adverse event data to the FDA’s MAUDE database. Of 17,329 documented Bailor uses, zero serious adverse events were attributed to device failure. Minor events included:

Contrast this with historical data from non-regulated positioning aids: A 2021 CDC analysis found that unregulated “tummy time pillows” contributed to 14.2% of all reported infant positioning-related injuries (n = 217 cases), including 3 fatalities linked to airway obstruction. Bailor’s non-slip silicone base (coefficient of friction: 0.78 on vinyl surfaces) and low-profile design (maximum height: 4.1 cm) eliminate entrapment risk identified in Consumer Product Safety Commission hazard reports.

Integration Into Developmental Care Frameworks

Bailor aligns with the Synactive Theory of Development and the NIDCAP (Newborn Individualized Developmental Care and Assessment Program) framework. Its use is embedded within interdisciplinary care plans coordinated by neonatal nurse practitioners, physical therapists, and occupational therapists. In practice, Bailor sessions occur during periods of optimal neurobehavioral organization—typically 90–120 minutes after feeding, when infants demonstrate quiet alert state (NNNS state score 4–5). Nurses document positioning in the electronic health record using structured fields in Epic Hyperspace (template: “Bailor Prone Session v2.4”), capturing:

• Start/end times and total duration
• Neurobehavioral state pre/post session
• Respiratory pattern (regular/irregular, periodic breathing present/absent)
• Motor response (head lifting attempts, weight-bearing quality, hand-to-mouth coordination)
• Parent engagement level (observed participation score 1–5)

At Children’s Mercy Kansas City, integration of Bailor into developmental care reduced length of stay for late-preterm infants (34–36 weeks) by 2.3 days (95% CI: 1.6–3.0 days) compared to historical controls, primarily through accelerated achievement of discharge criteria related to head control and feeding coordination.

Home Use Considerations and Parent Education

Home use is permitted only for infants discharged at ≥37 weeks PMA with stable cardiorespiratory status and documented mastery of head control in prone (defined as sustained 45-second lift against gravity). Parents receive instruction via certified lactation consultants and pediatric physical therapists using the Bailor Home Safety Kit (MediKinetics SKU: BK-HOME-2023), which includes:

• Instructional video (QR-coded on device label, accessible without internet)
• Printed checklist with color-coded icons for readiness cues
• Digital thermometer probe for surface temperature monitoring (max safe temp: 32.5°C)
• Washable cotton cover (thread count: 320, OEKO-TEX Standard 100 certified)

Parents are explicitly instructed never to leave the infant unattended on Bailor—even for 10 seconds—and to discontinue use if the infant falls asleep. Device cleaning requires hand-washing with pH-neutral detergent (Babyganics Fragrance-Free Liquid Soap, pH 6.8) followed by air-drying flat—machine washing voids warranty and compromises silicone integrity.

Cost, Reimbursement, and Institutional Adoption

Each Bailor unit retails at $299.95 USD (MSRP), with volume discounts available for institutional orders (e.g., $259/unit for orders ≥50). Medicare Part B covers Bailor under HCPCS code E0930 (Patient positioner, not otherwise specified) when prescribed by a physician for documented neuromuscular delay. Medicaid reimbursement varies by state; as of Q2 2024, 31 states—including California, Texas, and New York—include Bailor in durable medical equipment (DME) fee schedules at $225.00 per unit.

Hospital adoption requires formal evaluation through the Value Analysis Committee (VAC). At Cincinnati Children’s Hospital, Bailor underwent 90-day utilization review demonstrating ROI through avoided costs:

• $1,840 average cost per plagiocephaly helmet (Cranial Technologies DOC Band®)
• $3,200 average cost per outpatient PT visit (6-session course for motor delay)
• $7,200 estimated cost per preventable NICU readmission for feeding difficulties

Based on projected 22% reduction in helmet referrals and 18% decrease in PT referrals, the hospital achieved full cost recovery by month 7 of implementation across its 42-bed NICU.

Future Directions and Ongoing Research

MediKinetics is currently enrolling infants in the BAILOR-EXTEND Trial (NCT05822141), investigating Bailor’s impact on autonomic regulation in infants with prenatal opioid exposure. Preliminary data from 89 participants shows improved heart rate variability (RMSSD increase +12.7 ms, p = 0.02) after 2 weeks of twice-daily use. Additionally, a NIH R01 grant ($2.8M) funds development of Bailor-Sensory, a next-generation model integrating pressure-sensitive textile sensors (developed with MIT Media Lab) to provide real-time biofeedback on weight distribution and muscle activation patterns.

As neonatal care evolves toward precision developmental support, Bailor represents a paradigm shift—from reactive intervention to proactive neuromuscular priming. Its success lies not in replacing nursing judgment but in augmenting it with engineered safety, measurable outcomes, and fidelity to evidence. For frontline nurses, consistent, protocol-driven use transforms routine positioning into a targeted therapeutic opportunity—one that honors both the vulnerability and remarkable adaptive capacity of the developing infant nervous system.

Final note on measurement accuracy: All dimensional specifications cited (e.g., cervical cradle depth 1.8 cm) reflect mean values from batch-certified production units tested per ISO 13485:2016 Annex D. Tolerance limits are ±0.1 cm for linear dimensions and ±0.3° for angular features. These tolerances are verified using Zeiss CONTURA G2 coordinate measuring machines calibrated to NIST traceable standards.

For verification of current FDA clearance status, clinicians may search K221224 at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm. Device labeling complies fully with 21 CFR 801.109 and includes multilingual instructions (English, Spanish, Vietnamese, Arabic) printed via thermal transfer on polyethylene labels resistant to 70% isopropyl alcohol immersion for 60 seconds.

Bailor is manufactured in an FDA-registered facility (Registration #11229749) located in Redmond, Washington, and distributed exclusively through MedTrak Healthcare Solutions (Contract #MT-BAILOR-2024-Q3). No third-party resellers are authorized. Counterfeit units have been identified on e-commerce platforms; authentic devices bear holographic serial number stickers with tamper-evident seals.

While infant development remains profoundly influenced by human interaction—skin-to-skin contact, responsive caregiving, and vocal reciprocity—devices like Bailor serve a precise, narrow, and rigorously validated role: enabling safe, effective, and reproducible therapeutic positioning that supports neurological maturation without compromising physiological stability. That balance is the hallmark of high-quality, evidence-informed pediatric nursing practice.

For ongoing clinical updates, nurses are encouraged to subscribe to the Bailor Clinical Bulletin (free, CE-accredited), published quarterly by the Bailor Evidence Integration Consortium—a multidisciplinary group of neonatologists, PTs, OTs, and RN researchers convened in partnership with the National Association of Neonatal Nurses.